Intelligence · Patents
Patents expiring in 2043
Annual patent cliff calendar for 2043 — US pharmaceutical patents by expiration date.
- Patents
- 1,718
Quick answer
1,718 indexed pharmaceutical patents have expiration dates in 2043. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11583541
Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
granted -
US 11583529
Treatment of inflammatory disorders
granted -
US 11583578
Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery
granted -
US 11584780
Adeno-associated virus capsid proteins
granted -
US 11583538
Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
granted -
US 11582956
Recombinant adenovirus-based interferon biotherapeutics in swine
granted -
US 11584758
RIP1K inhibitors
granted -
US 11584737
Heterocyclic compound
granted -
US 11584755
Dihydrothieno[3,2-b]pyridine compounds
granted -
US 11584735
Solid forms of a plasma kallikrein inhibitor and salts thereof
granted -
US 11584748
Spirocyclic compounds
granted -
US 11583540
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
granted -
US 11583584
Stable protein compositions and methods of their use
granted -
US 11583530
Compounds for the prevention and treatment of medical disorders and uses thereof
granted -
US 11584966
Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof
granted -
US 11583489
Flushable wipe and method of forming the same
granted -
US 11583526
Treatment of prostate cancer
granted -
US 11583556
Modified cells and methods of therapy
granted -
US 11584933
RNA interference in ocular indications
granted -
US 11583557
Placenta-derived multipotent stem cells
granted -
US 11583548
Compounds and methods for reducing ATXN3 expression
granted -
US 11584733
Selective histone deacetylase inhibitors for the treatment of human disease
granted -
US 11584760
Dithio ETP derivatives
granted -
US 11584923
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
granted -
US 11590170
Chimeric antigen receptor
granted -
US 11590171
Targeted replacement of endogenous T cell receptors
granted -
US 11591330
HIF-2a small-molecule inhibitor and use thereof
granted -
US 11590204
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted -
US 11590205
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
granted -
US 11590223
Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
granted -
US 11591304
SLC26A3 inhibitors and use thereof
granted -
US 11590197
Agents targeting inhibitor of apoptosis proteins
granted -
US 11590221
Dengue vaccine unit dose and administration thereof
granted -
US 11594345
Method for producing Ac-225 from Ra-226
granted -
US 11591579
Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
granted -
US 11590222
Antibodies that bind human C6 and uses thereof
granted -
US 11591613
Retroviral and lentiviral vectors
granted -
US 11591372
Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof
granted -
US 11591369
Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
granted -
US 11591402
Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
granted -
US 11590234
Hyperbranched polymers and polyplexes and DNA or RNA delivery systems including the same
granted -
US 11591622
Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder
granted -
US 11591332
IRAK degraders and uses thereof
granted -
US 11591316
Compounds, compositions, and methods
granted -
US 11590111
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
granted -
US 11590135
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
granted -
US 11594302
High resolution allele identification
granted -
US 11591381
Gene-edited natural killer cells
granted
Frequently asked questions
How many pharma patents expire in 2043?
1,718 published patents in our USPTO index have expiration dates falling in calendar year 2043.